bluebird bio (BLUE)
NASDAQ:BLUE

Bluebird Bio (BLUE) Stock Forecast & Price Target

2,080 Followers
See the Price Targets and Ratings of:

BLUE Analyst Ratings

Hold
7Ratings
1 Buy
5 Hold
1 Sell
Based on 7 analysts giving stock ratings to
Bluebird
Bio
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BLUE Stock 12 Months Forecast

Average Price Target

$8.00
▼(-0.12% Downside)
Based on 7 Wall Street analysts offering 12 month price targets for Bluebird Bio in the last 3 months. The average price target is $8.00 with a high forecast of $10.00 and a low forecast of $4.00. The average price target represents a -0.12% change from the last price of $8.01.
Highest Price Target$10.00Average Price Target$8.00Lowest Price Target$4.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Cowen & Co.
Hold
Downgraded
Bluebird Bio downgraded to Market Perform from Outperform at CowenBluebird Bio downgraded to Market Perform from Outperform at Cowen
Wells Fargo
$8.00
Hold
-0.12%
Downside
Reiterated
Analysts Have Conflicting Sentiments on These Healthcare Companies: Brickell Biotech (NASDAQ: BBI), Bluebird Bio (NASDAQ: BLUE) and Aurinia Pharmaceuticals (NASDAQ: AUPH)
BMO Capital
$13.00
Hold
62.30%
Upside
Reiterated
bluebird bio (BLUE) Clinical Hold Raises Even More Safety Questions, Outlook is Cautious - BMO Capital MarketsCommenting on the announcement, BMO Capital Markets analyst Matthew Luchini believes the announcement raises additional safety concerns over the companys SCD program: "New uncertainty around SCD program following partial clinical hold.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

BLUE Financial Forecast

BLUE Earnings Forecast
Next quarter’s earnings estimate for BLUE is -$0.29 with a range of -$1.08 to $1.47. The previous quarter’s EPS was -$0.94. BLUE beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.45% of the time in the same period. In the last calendar year BLUE has Underperformed its overall industry.
Next quarter’s earnings estimate for BLUE is -$0.29 with a range of -$1.08 to $1.47. The previous quarter’s EPS was -$0.94. BLUE beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.45% of the time in the same period. In the last calendar year BLUE has Underperformed its overall industry.
BLUE Sales Forecast
Next quarter’s sales forecast for BLUE is $30.90M with a range of $0.00 to $210.00M. The previous quarter’s sales results were $71.00K. BLUE beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 42.90% of the time in the same period. In the last calendar year BLUE has Outperformed its overall industry.
Next quarter’s sales forecast for BLUE is $30.90M with a range of $0.00 to $210.00M. The previous quarter’s sales results were $71.00K. BLUE beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 42.90% of the time in the same period. In the last calendar year BLUE has Outperformed its overall industry.
BLUE Analyst Recommendation Trends
In the current month, BLUE has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BLUE average analyst price target in the past 3 months is $8.00
In the current month, BLUE has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BLUE average analyst price target in the past 3 months is $8.00

BLUE Stock Forecast FAQ

What is BLUE’s average 12-month price target, according to analysts?
Based on analyst ratings, Bluebird Bio’s 12-month average price target is $8.00.
    What is BLUE’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for BLUE, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is BLUE a Buy, Sell or Hold?
        Bluebird Bio has a conensus rating of Hold which is based on 1 buy ratings, 5 hold ratings and 1 sell ratings.
          What is Bluebird Bio’s price target?
          The average price target for Bluebird Bio is $8.00. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $10.00 ,the lowest forecast is $4.00. The average price target represents -0.12% Decrease from the current price of $8.01.
            What do analysts say about Bluebird Bio?
            Bluebird Bio’s analyst rating consensus is a ‘Hold. This is based on the ratings of 7 Wall Streets Analysts.

              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis